Technical Analysis for IMDZ - Immune Design Corp.

Grade Last Price % Change Price Change
grade A 5.85 0.00% 0.00
IMDZ closed unchanged on Monday, April 1, 2019, on 9 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Extremely Strong Up Up Flat
See historical IMDZ trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 311.97%
NR7 Range Contraction 311.97%
Inside Day Range Contraction 311.97%
Oversold Stochastic Weakness 311.97%
MACD Bearish Centerline Cross Bearish 320.86%
Stochastic Reached Oversold Weakness 320.86%
Down 3 Days in a Row Weakness 320.86%
Down 4 Days in a Row Weakness 320.86%
Down 5 Days in a Row Weakness 320.86%
Lower Bollinger Band Touch Weakness 320.86%

Older signals for IMDZ ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Immune Design Corp., a clinical-stage immunotherapy company, focuses on the development of novel immune-based therapies based on its DCVex and GLAAS discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. The company was formerly known as VaccSys Inc. and changed its name to Immune Design Corp. in June, 2008. The company was founded in 2008 and is headquartered in Seattle, Washington.
Medicine Cancer Clinical Medicine Immunotherapy Cancer Treatments Breast Cancer Non Small Cell Lung Cancer Cancer Immunotherapy Ovarian Cancer Melanoma Targeted Therapy Solid Tumor Merkel Cell Carcinoma Chronic Conditions Sarcoma
Is IMDZ a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.85
52 Week Low 1.1
Average Volume 1,175,337
200-Day Moving Average 3.067
50-Day Moving Average 3.9235
20-Day Moving Average 5.842
10-Day Moving Average 5.846
Average True Range 0.0665
ADX 77.35
+DI 68.6895
-DI 5.0785
Chandelier Exit (Long, 3 ATRs ) 5.6505
Chandelier Exit (Short, 3 ATRs ) 6.0195
Upper Bollinger Band 5.8582
Lower Bollinger Band 5.8258
Percent B (%b) 0.75
BandWidth 0.554605
MACD Line 0.4686
MACD Signal Line 0.6157
MACD Histogram -0.1471
Fundamentals Value
Market Cap 149.87 Million
Num Shares 25.6 Million
EPS -2.52
Price-to-Earnings (P/E) Ratio -2.32
Price-to-Sales 6.15
Price-to-Book 1.37
PEG Ratio -0.34
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.87
Resistance 3 (R3) 5.86 5.86 5.86
Resistance 2 (R2) 5.86 5.85 5.86 5.86
Resistance 1 (R1) 5.85 5.85 5.86 5.86 5.86
Pivot Point 5.85 5.85 5.85 5.85 5.85
Support 1 (S1) 5.84 5.84 5.85 5.85 5.84
Support 2 (S2) 5.84 5.84 5.84 5.84
Support 3 (S3) 5.83 5.84 5.84
Support 4 (S4) 5.84